Pharmacology and Therapeutics

Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports
Isaac V. Cohen, Tigran Makunts, Talar Moumedjian, Masara Issa, Ruben Abagyan

medRxiv 2020.05.19.20107227; doi: https://doi.org/10.1101/2020.05.19.20107227

Add to Selected Citations
Investigation on the interaction between nifedipine and ritonavir containing antivirus regimens: a physiologically-based pharmacokinetic/pharmacodynamic analysis
Wan-jie Niu, Si-ze Li, Sha-sha Jin, Xi-ying Lin, Meng-wan Zhang, Wei-min Cai, Ming-kang Zhong, Xiao-qiang Xiang, Zheng Jiao

medRxiv 2020.05.19.20106658; doi: https://doi.org/10.1101/2020.05.19.20106658

Add to Selected Citations
Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol
Hajira Dambha-Miller, Ali Albasri, Sam Hodgson, Chris Wilcox, Nazrul Islam, Shareen Khan, Paul Little, Simon J Griffin

medRxiv 2020.05.25.20100438; doi: https://doi.org/10.1101/2020.05.25.20100438

Add to Selected Citations
Low blood sodium increases risk and severity of COVID-19: a systematic review, meta-analysis and retrospective cohort study
Yi Luo, Yirong Li, Jiapei Dai

medRxiv 2020.05.18.20102509; doi: https://doi.org/10.1101/2020.05.18.20102509

Add to Selected Citations
Assessment of medication Dosage Adjustment in Hospitalized Patients with Chronic Kidney Disease
Zair Hassan, Iftikhar Ali, Arslan Rahat Ullah, Raheel Ahmed, Shakeel Rehman, Azizullah Khan

medRxiv 2020.05.04.20090787; doi: https://doi.org/10.1101/2020.05.04.20090787

Add to Selected Citations
The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Vicente Martinez-Vizcaino, Arthur E. Mesas, Iván Cavero-Redondo, Alicia Saz-Lara, Irene Sequí-Dominguez, Carlos Pascual-Morena, Celia Álvarez-Bueno

medRxiv 2020.05.05.20091785; doi: https://doi.org/10.1101/2020.05.05.20091785

Add to Selected Citations
Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19
Umesh Devappa Suranagi, Harmeet Singh Rehan, Nitesh Goyal

medRxiv 2020.04.16.20068205; doi: https://doi.org/10.1101/2020.04.16.20068205

Add to Selected Citations
Cognitive decline associated with anticholinergics, benzodiazepines, and Z-drugs: findings from The Irish Longitudinal Study on Ageing (TILDA)
Frank Moriarty, George M Savva, Carlota M Grossi, Kathleen Bennett, Chris Fox, Ian Maidment, Yoon K Loke, Nicholas Steel, Rose Anne Kenny, Kathryn Richardson

medRxiv 2020.05.09.20095661; doi: https://doi.org/10.1101/2020.05.09.20095661

Add to Selected Citations
Dopaminergic stimulants and risk of Parkinson’s disease
Michael Wainberg, Dipender Gill, Bowen Su, Mike A. Nalls, Robert R. Graham, Sudeshna Das, Ioanna Tzoulaki, Nasa Sinnott-Armstrong, Manuel A. Rivas

medRxiv 2020.05.06.20089748; doi: https://doi.org/10.1101/2020.05.06.20089748

Add to Selected Citations
A systematic review and meta-analysis to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers
Abhinav Grover, Mansi Oberoi

medRxiv 2020.04.29.20085787; doi: https://doi.org/10.1101/2020.04.29.20085787

Add to Selected Citations

Pharmacology and Therapeutics

Pages